Products developed under the strictest international standards to ensure therapeutic efficacy and diagnostic safety.
FDG is a radiopharmaceutical widely used in oncological, neurological, and cardiological applications, enabling metabolic evaluation through PET/CT.
PSMA 1007 18F is indicated for the detection of prostate cancer via PET/CT, offering high sensitivity and excellent image definition.